Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 11:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,051 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diabetic Clear all
Completed Phase 1Phase 2 Interventional

Use of a Nutritional Supplement to Treat Diabetic Symptoms in HIV-Infected Adults

NCT00109746
View directory record Official record
Conditions
Insulin Resistance, HIV Infections
Interventions
chromium picolinate
Dietary Supplement
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Mar 23, 2016 · Synced Oct 22, 2026, 11:41 PM EDT
Completed Phase 2 Interventional Results available

Effectiveness of Metformin Compared to Insulin in Pregnant Women With Mild Preexisting or Early Gestational Diabetes

NCT00835861
View directory record Official record
Conditions
Non Insulin Dependent Diabetes, Pregnancy
Interventions
Metformin, Insulin
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Oct 22, 2026, 11:41 PM EDT
Not listed Not applicable Interventional

Prospective, Multicenter, RCT of the Tenex Ultrasound System

NCT06137222
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
Tenex TXB MicroTip Ultrasound system plus SOC, Standard of Care for diabetic foot ulcer
Device · Other
Lead sponsor
Tenex Health Inc.
Industry
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Mobile, Alabama • St. George, Utah
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 22, 2026, 11:41 PM EDT
Completed Phase 4 Interventional

Ocular Safety and Usability Study for FYB203 PFS

NCT06708637
View directory record Official record
Conditions
Age-Related Macular Degeneration, Branch Retinal Vein Occlusion with Macular Edema, Central Retinal Vein Occlusion with Macular Edema, Diabetic Macular Edema, Diabetic Retinopathy
Interventions
FYB203 2 mg (0.05 mL of 40 mg/mL)
Drug
Lead sponsor
Formycon AG
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
4
States / cities
Campbell, California • Long Beach, California • Redlands, California + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2024 · Synced Oct 22, 2026, 11:41 PM EDT
Recruiting Not applicable Interventional

Miro3D Wound Matrix for Treatment of Diabetic Foot Ulcers

NCT07632001
View directory record Official record
Conditions
Diabetic Foot Ulcers (DFUs), Diabetic Foot, Chronic Wounds
Interventions
Miro3D Wound Matrix, Standard of Care
Device · Other
Lead sponsor
Reprise Biomedical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
14
States / cities
Phoenix, Arizona • Coconut Creek, Florida • Coral Gables, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 22, 2026, 11:41 PM EDT
Active, not recruiting Not applicable Interventional

Remote Temperature and Visual Monitoring To Help Manage Diabetic Foot Ulcers

NCT06782386
View directory record Official record
Conditions
Diabetic Foot Ulcer (DFU)
Interventions
OneStep Foot Scanner
Device
Lead sponsor
Bluedrop Medical Limited
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
North Port, Florida • Monroeville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 22, 2026, 11:41 PM EDT
Completed No phase listed Observational

Myocardial Perfusion Study to Detect Coronary Microvascular Abnormality in Diabetic Patients With Nonfatal Myocardial Infarction

NCT01749683
View directory record Official record
Conditions
Myocardial Infarction
Interventions
Not listed
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 71 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Oct 20, 2021 · Synced Oct 22, 2026, 11:41 PM EDT
Withdrawn Phase 4 Interventional

Evaluating the Effect of Aliskiren Versus HCTZ on Coronary Flow Reserve in Hypertensive Type II Diabetics

NCT00994253
View directory record Official record
Conditions
Hypertension, Diabetes Type 2
Interventions
Aliskiren, Hydrochlorothiazide
Drug
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 2, 2017 · Synced Oct 22, 2026, 11:41 PM EDT
Not listed Not applicable Interventional

Exploratory Study of the Efficacy of Standard of Care Revascularization of the Lower Extremity

NCT04720170
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy
Interventions
Revascularization
Procedure
Lead sponsor
Diabetes and Glandular Disease Clinic
Industry
Eligibility
30 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Oct 22, 2026, 11:41 PM EDT
Completed Phase 1 Interventional Results available

Use of Ranibizumab to Treat Rubeosis in Diabetics Prior to Cataract Surgery

NCT01069341
View directory record Official record
Conditions
Rubeosis Iridis, Proliferative Diabetic Retinopathy
Interventions
Ranibizumab
Drug
Lead sponsor
Bhagat, Neelakshi, M.D., M.P.H.
Individual
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 4, 2012 · Synced Oct 22, 2026, 11:41 PM EDT
Completed Not applicable Interventional Results available

Triamcinolone vs. Laser for Diabetic Macular Edema

NCT00229931
View directory record Official record
Conditions
DIABETIC MACULAR EDEMA
Interventions
Triamcinolone acetonide, laser
Drug · Procedure
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Dec 28, 2023 · Synced Oct 22, 2026, 11:41 PM EDT
Completed Phase 3 Interventional Results available

DRCR.Net Aflibercept vs. Bevacizumab + Deferred Aflibercept for the Treatment of CI-DME

NCT03321513
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
intravitreous aflibercept, Bevacizumab + Deferred Aflibercept Group
Drug
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
54
States / cities
Campbell, California • Glendale, California • Loma Linda, California + 46 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 22, 2026, 11:41 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A Study of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME

NCT06957080
View directory record Official record
Conditions
Diabetic Macular Edema (DME)
Interventions
Remigromig, Ranibizumab
Drug
Lead sponsor
EyeBiotech Ltd.
Industry
Eligibility
18 Years and older
Enrollment
1,054 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
107
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 96 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 22, 2026, 11:41 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Prandial Inhalation of Technosphere/Insulin in Combination With Metformin or Technosphere/Insulin Alone Versus 2 Oral Anti-Diabetic Agents in Subjects With Type 2 Diabetes

NCT00332488
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Technosphere Insulin, Metformin & Secretagogues, Technosphere Insulin & Metformin
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
547 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
43
States / cities
Birmingham, Alabama • Phoenix, Arizona • Chula Vista, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2014 · Synced Oct 22, 2026, 11:41 PM EDT
Withdrawn Phase 1 Interventional

Intranasal Delivery of Octreotide for Treatment of Diabetic Macular Edema

NCT06881888
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Octreotide (drug), Placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 22, 2026, 11:41 PM EDT
Completed Phase 2 Interventional

A Safety and Efficacy Study in Subjects With Diabetic Neuropathic Pain

NCT00548925
View directory record Official record
Conditions
Diabetic Neuropathic Pain
Interventions
ABT-894, placebo
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 75 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
12
States / cities
Spring Valley, California • Walnut Creek, California • Hollywood, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2013 · Synced Oct 22, 2026, 11:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Assess Screening for Diabetic Retinopathy Using Retinal Camera in Family Medicine Clinic

NCT03828890
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Screening eye exam using Optos technology
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 2, 2020 · Synced Oct 22, 2026, 11:41 PM EDT
Not listed Phase 2 Interventional

Lidorestat (IDD 676) for the Treatment of Diabetic Neuropathy

NCT00043797
View directory record Official record
Conditions
Diabetic Polyneuropathy
Interventions
Lidorestat (IDD 676)
Drug
Lead sponsor
The Institute for Diabetes Discovery, LLC
Industry
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
11
States / cities
Scottsdale, Arizona • Glendale, California • Greenbrae, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 22, 2026, 11:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Reactive Oxygen Species in the Pathogenesis of Diabetic Complications

NCT00703989
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
benfotiamine, α-lipoic acid
Dietary Supplement
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years to 45 Years · Male only
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Nov 12, 2019 · Synced Oct 22, 2026, 11:41 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

The Effect of TLR4 Inhibition in Obese and Type 2 Diabetic Subjects

NCT02267317
View directory record Official record
Conditions
Insulin Sensitivity
Interventions
Eritoran, D5W
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Oct 22, 2026, 11:41 PM EDT
Active, not recruiting Phase 3 Interventional

COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME

NCT07449936
View directory record Official record
Conditions
Diabetic Macular Edema, DME, Diabetic Macular Edema (DME)
Interventions
EYP-1901, Aflibercept (2.0 mg)
Drug
Lead sponsor
EyePoint Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
53
States / cities
Bakersfield, California • Encino, California • Glendale, California + 49 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 22, 2026, 11:41 PM EDT
Active, not recruiting Not applicable Interventional

IDEAL: Efficacy of Porcine Placental Extracellular Matrix Augmented Plus Standard of Care (SOC) Versus SOC Alone for the Management of Diabetic Foot Ulcers

NCT06616844
View directory record Official record
Conditions
Wound Heal, Ulcer
Interventions
InnovaMatrix® AC
Device
Lead sponsor
ConvaTec Inc.
Industry
Eligibility
18 Years and older
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
21
States / cities
Fresno, California • Los Angeles, California • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 22, 2026, 11:41 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Diabetic Ketoacidosis and Its Impact on the Brain

NCT01753934
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
4 Years to 16 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Oct 22, 2026, 11:41 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IVT MHU650 in Macular Edema Patients

NCT04635800
View directory record Official record
Conditions
Macular Edema, Diabetic Macular Edema, Neovascular Age-related Macular Degeneration, Retinal Vein Occlusion
Interventions
MHU650
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 90 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
Huntington Beach, California • Honolulu, Hawaii • Hagerstown, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated May 18, 2025 · Synced Oct 22, 2026, 11:41 PM EDT